{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-025891","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2022-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.331017+00:00","generated_at":"2026-06-23T09:43:16.914076+00:00","sec_items":["1.01","3.03","5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Celcuity appoints Dr. Polly Murphy to Board; reduces warrant shares to 70K","bullets":["Warrant amended: shares reduced from 138,000 to 70,000; exercise period extended to Sept 19, 2025.","Board expanded to 7 directors; Dr. Polly Murphy elected as independent director, effective immediately.","Dr. Murphy brings 20+ years of pharma biz dev experience including 12 years at Pfizer; currently CBO of UroGen Pharma.","Dr. Murphy granted options: 16,300 shares vesting by 2023 annual meeting or April 30, 2023; plus 10,000 shares vesting over 4 years.","Company expects to dose first patient in Phase 3 gedatolisib study for HR+/HER2- breast cancer in next few months."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-025891","json":"https://secwatch.observer/filing/0001493152-22-025891.json","markdown":"https://secwatch.observer/filing/0001493152-22-025891.md","text":"https://secwatch.observer/filing/0001493152-22-025891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315222025891/0001493152-22-025891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315222025891/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:43:16.914076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb2f5c0b57","claim":"Polly Murphy was elected as Director at Celcuity Inc..","evidence_excerpt":"On September 12, 2022, the Board of Directors (the “Board”) of the Company, voted to increase the size of the Board from six members to seven members and to elect Polly Murphy, D.V.M., Ph.D. as a new director to fill the resulting vacancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000149315222025891/0001493152-22-025891-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}